Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jul 31:16:1638102.
doi: 10.3389/fimmu.2025.1638102. eCollection 2025.

M1 macrophages - unexpected contribution to tumor progression

Affiliations
Review

M1 macrophages - unexpected contribution to tumor progression

Olga V Kovaleva et al. Front Immunol. .

Abstract

The anti-tumor role of the immune system has long been associated with interferon-γ-mediated activation of immune cells and their ability to recognize and eliminate transformed cells. Fundamental principles of tumor immunoediting describe a dynamic interplay between the immune system and neoplastic cells, wherein immune pressure can paradoxically shape tumor evolution. Within this context, macrophages, natural killer cells, and T lymphocytes are central effectors of anti-tumor immunity. Traditionally, macrophages exhibiting M1 phenotype are characterized by high cytotoxic potential and considered important contributors to tumor eradication. In contrast, M2-polarized tumor-associated macrophages are associated with immune suppression and tumor progression. However, recent evidence challenges this binary paradigm. It is increasingly evident that M1 macrophages, while initially exerting anti-tumor effects, can also promote tumor progression by applying sustained cytotoxic pressure that selects for more malignant and immune-resistant tumor clones. This phenomenon represents an unexpected and overlooked contribution of cytotoxic macrophages to tumor progression. In this review, we examine the complex, context-dependent function of M1 macrophages and reassess current strategies aimed at enhancing their cytotoxicity. While such approaches may offer short-term benefits, they risk driving clonal selection of aggressive, immune-evasive tumor cells. Therefore, we propose a paradigm shift: instead of promoting M1 polarization alone, therapeutic strategies should consider the broader consequences of macrophage-tumor interactions. A nuanced understanding of macrophage plasticity and tumor dynamics is essential for designing effective immunotherapies. Recognizing the paradoxical role of M1 macrophages is critical to avoiding unintended support of tumor evolution and improving treatment outcomes.

Keywords: ADCC; ADCP; immunotherapy; inflammation; innate immunity; macrophage; tumor.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.

Figures

Figure 1
Figure 1
Cytotoxic macrophage-mediated selection of tumor cells. The left panel depicts a heterogeneous tumor microenvironment where large amount of M1 macrophages exert cytotoxic pressure (red arrows), leading to the elimination of sensitive tumor cells and the survival of resistant clones, culminating in the emergence of a resistant tumor. Concurrently, M2 macrophages support tumor growth (green arrows). In contrast, the right panel shows a balanced microenvironment where such selective pressure is low, allowing for the persistence of a mixed tumor cell population without the dominance of resistant clones, resulting in a sensitive tumor phenotype. This model illustrates how cytotoxic M1 can paradoxically contribute to tumor evolution.

Similar articles

References

    1. Xu M, Zhang T, Xia R, Wei Y, Wei X. Targeting the tumor stroma for cancer therapy. Mol cancer. (2022) 21:208. doi: 10.1186/s12943-022-01670-1, PMID: - DOI - PMC - PubMed
    1. Li HX, Wang SQ, Lian ZX, Deng SL, Yu K. Relationship between tumor infiltrating immune cells and tumor metastasis and its prognostic value in cancer. Cells. (2022) 12:64. doi: 10.3390/cells12010064, PMID: - DOI - PMC - PubMed
    1. Finn OJ. Human tumor antigens yesterday, today, and tomorrow. Cancer Immunol Res. (2017) 5:347–54. doi: 10.1158/2326-6066.CIR-17-0112, PMID: - DOI - PMC - PubMed
    1. Sobhani N, Tardiel-Cyril DR, Davtyan A, Generali D, Roudi R, Li Y. CTLA-4 in regulatory T cells for cancer immunotherapy. Cancers (Basel). (2021) 13:1440. doi: 10.3390/cancers13061440, PMID: - DOI - PMC - PubMed
    1. Sanchez-Reyes K, Bravo-Cuellar A, Hernandez-Flores G, Lerma-Diaz JM, Jave-Suarez LF, Gomez-Lomeli P, et al. Cervical cancer cell supernatants induce a phenotypic switch from U937-derived macrophage-activated M1 state into M2-like suppressor phenotype with change in Toll-like receptor profile. BioMed Res Int. (2014) 2014:683068. doi: 10.1155/2014/683068, PMID: - DOI - PMC - PubMed

LinkOut - more resources